Eledon Pharmaceuticals, Inc.
ELDN
$3.55
-$0.03-0.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.15% | -8.75% | 33.36% | 38.43% | 48.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.32% | 17.96% | 53.80% | 87.40% | 81.65% |
| Operating Income | -11.32% | -17.96% | -53.80% | -87.40% | -81.65% |
| Income Before Tax | -319.57% | -27.49% | -266.27% | 113.89% | 85.61% |
| Income Tax Expenses | -91.88% | -91.88% | -- | -- | -- |
| Earnings from Continuing Operations | -310.26% | -26.07% | -268.26% | 113.49% | 85.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -310.26% | -26.07% | -268.26% | 113.49% | 85.28% |
| EBIT | -11.32% | -17.96% | -53.80% | -87.40% | -81.65% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -106.30% | 51.97% | 22.19% | 128.97% | 93.50% |
| Normalized Basic EPS | -171.06% | 48.34% | 24.05% | 121.03% | 95.05% |
| EPS Diluted | 74.02% | 84.25% | 69.78% | 68.62% | 48.36% |
| Normalized Diluted EPS | -94.84% | 52.81% | 28.95% | 118.07% | 93.12% |
| Average Basic Shares Outstanding | 33.99% | 127.14% | 168.90% | 194.68% | 212.50% |
| Average Diluted Shares Outstanding | 32.67% | 123.09% | 162.90% | 197.34% | 215.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |